[{"from": "human", "value": "Could you provide a description of this molecule? [C][C][C@@H1][Branch1][=Branch1][C@@H1][Branch1][C][C][O][N][C][=N][C][=Branch2][Ring1][Ring2][=C][C][=Branch1][Ring2][=N][Ring1][=Branch1][N][Branch1][Branch1][C][=N][Ring1][=Branch1][C][Branch1][C][C][C][N][C][C][=C][N][=C][Branch1][=Branch1][C][=C][Ring1][=Branch1][C][C]"}, {"from": "gpt", "value": "The molecule is an orally bioavailable inhibitor of cyclin dependent kinases 2, 5 and 9 (CDK2/5/9), with potential antineoplastic and chemoprotective activities. Upon oral administration, fadraciclib selectively binds to and inhibits the activity of CDK2, 5 and 9, which leads to inhibition of CDK2, 5 and 9-dependent cellular pathways, downregulation of genes involved in the pro-survival pathway, prevention of the activation of DNA double-strand break repair pathways, and induction of both cell cycle arrest and apoptosis. This inhibits the proliferation of CDK2/5/9-overexpressing tumor cells. In addition, CYC065 protects hematopoietic stem and progenitor cells (HSPCs), prevents myelosuppression, and preserves the function of the bone marrow. CDKs are serine/threonine kinases involved in the regulation of the cell cycle and may be overexpressed in certain cancer cell types; they play key roles in tumor cell proliferation, the regulation of transcription, and DNA damage repair."}]